F-Star Therapeutics Inc. (FSTX) to Present FS120 Phase 1 Trial-in-Progress Update at ESMO

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that the Company will present a trial in progress update on FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist, at the European Society for Medical Oncology 2021 Conference, taking place virtually, September 16th-21st.

The poster, entitled “A First-in-Human Phase 1 Study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies” is presented by Kyriakos P. Papadopoulos (START, San Antonio, Texas) and describes the design of a first-in-human Phase 1 clinical trial (NCT04648202) to assess the safety, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of FS120 in patients with advanced malignancies.

This study comprises an Accelerated Dose Titration (ADT) component followed by a 3+3 design. Enrollment of the ADT portion of the study is complete, and the Company anticipates providing a further update on the study progress later this year.

Key findings include:

• Preclinical data from pivotal GLP Non-Human primate (NHP) study indicate a wide therapeutic window supporting the clinical study design. FS120 was well tolerated in NHP with a HNSTD (highest non-severely toxic dose) of 30mg/kg with limited and minimal changes in clinical chemistry measurements relating to liver model function.
• Pharmacodynamic biomarkers indicative of FS120 pharmacology, including increases in proliferation of CD4+ and CD8+ T cell and NK cell models, were observed in the NHP study and plateaued at the highest dose level. These pharmacodynamic markers are being used in the clinical study to determine a pharmacologically active dose in humans.

Safety and PK/PD data from this study will be used to trigger the initiation of the previously announced FS120 and KEYTRUDA® (pembrolizumab) combination study, scheduled to start in Q3 2022.

Louis Kayitalire, Chief Medical Officer of F-star, said, “We are pleased to share this update on our first-in-class OX40 and CD137 tetravalent dual T cell agonist, FS120. In contrast to first generation T cell agonists, FS120 activates through concurrent binding to both CD4 and CD8 T cells. These latest data on FS120 are encouraging, and indicate that FS120 has the potential to be active and well-tolerated at high dose levels. With enrollment in the Accelerated Dose Titration study completed, we look forward to providing additional updates later this year and initiating the next study of FS120 in combination with KEYTRUDA (MSD’s anti-PD-1 therapy), in 2022.”

You May Also Be Interested In

• AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
• Belite Bio (BLTE) Announces $25 Million Registered Direct Offering
• Exxon (XOM) shares slip as Q1 earnings falls short of analyst estimates